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Excessive accumulation of triacylglycerol in periph-
eral tissues is tightly associated with obesity and
has been identified as an independent risk factor
for insulin resistance, type 2 diabetes, and cardio-
vascular complications. Here we show that ablation
of carboxylesterase 3 (Ces3)/triacylglycerol hydro-
lase (TGH) expression in mice (Tgh/) results in
decreased plasma triacylglycerol, apolipoprotein B,
and fatty acid levels in both fasted and fed states.
Despite the attenuation of very low-density lipopro-
tein secretion, TGH deficiency does not increase
hepatic triacylglycerol levels. Tgh/ mice exhibit
increased food intake, respiratory quotient, and
energy expenditure without change in body weight.
These metabolic changes are accompanied by
improved insulin sensitivity and glucose tolerance.
Tgh/ mice have smaller sized pancreatic islets
but maintain normal glucose-stimulated insulin
secretion. These studies demonstrate the potential
of TGH as a therapeutic target for lowering blood
lipid levels.
INTRODUCTION
The major function of hepatic very low-density lipoproteins
(VLDLs) is to deliver triacylglycerol (TG) from the liver to periph-
eral tissues. Increased plasma TG levels represent an indepen-
dent risk factor for cardiovascular disease (Carmena et al.,
2004; Havel, 1990). Additionally, insulin resistance, hyperten-
sion, and visceral obesity are also characterized by elevated
plasma concentration of TG-rich lipoproteins (Carmena et al.,
2004; Ginsberg et al., 2005; Schaefer et al., 2002). Because of
the potential for pharmacological intervention, the mechanism
of VLDL assembly and secretion in the liver has attracted consid-
erable interest (Chahil and Ginsberg, 2006; Cuchel et al., 2007;
Lieu et al., 2003).CeAccumulating evidence suggests that the formation of apoli-
poprotein B (apoB)-containing lipoproteins is accomplished
through two steps (Fisher and Ginsberg, 2002; Kulinski et al.,
2002; Raabe et al., 1999; Vukmirica et al., 2003). Initially,
a primordial relatively lipid-poor particle is formed during apoB
translocation into the lumen of the endoplasmic reticulum (ER),
and this process requires active new synthesis of lipids,
including TG. Subsequently, apoB acquires the bulk of core
lipids (mainly TG) to form a mature VLDL. The central role of
TG in the assembly and secretion of apoB lipoproteins has
been demonstrated in cultured hepatocytes (Fisher and Gins-
berg, 2002; Gibbons et al., 2004). The majority (60%–70%) of
VLDL-TG secreted from hepatocytes is derived from stored
TG via a process of lipolysis and re-esterification (Gibbons
et al., 2000, 2004; Wiggins and Gibbons, 1992; Yang et al.,
1995, 1996).
An ER-localized triacylglycerol hydrolase (TGH), also termed
carboxylesterase 3 (Ces3) in mice and carboxylesterase 1
(CES1) in humans, has been suggested to play a role in the provi-
sion of substrates for the assembly of apoB-containing lipopro-
teins (Dolinsky et al., 2004a, 2004b; Lehner and Verger, 1997).
Expression of TGH cDNA in McArdle RH7777 cells increased
lipolysis of preformed TG stores and augmented TG secretion
and levels of apoB100 in the VLDL density range (Gilham et al.,
2005; Lehner and Vance, 1999). Fasting plasma TG and apoB
levels were increased in transgenic mice that express human
TGH specifically in the liver (Wei et al., 2007a). Inhibition of
lipolysis in intact primary rat hepatocytes by a cell-permeable
TGH-specific inhibitor resulted in decreased secretion of apoB
and TG (Gilham et al., 2003). These data support an active role
for TGH in the mobilization of intracellular TG for VLDL assembly.
ApoB lipidation is a potential pharmacological target for the
treatment of hypertriglyceridemia and associated cardiovascular
and metabolic diseases. One major concern is that inhibition of
hepatic VLDL secretion may lead to hepatic steatosis. Such
condition has been observed upon chemical inhibition or genetic
disruption of microsomal triglyceride transfer protein (MTP)
(Chandler et al., 2003; Cuchel et al., 2007; Raabe et al., 1999).
Hepatic steatosis is strongly associated with decreased insulin
sensitivity (Marchesini et al., 2005; Petersen and Shulman,
2006; Savage et al., 2007), although recent data suggest thatll Metabolism 11, 183–193, March 3, 2010 ª2010 Elsevier Inc. 183
Figure 1. Generation of TGH-Deficient Mice
(A) PCR of genomic DNA.
(B and C) Absence of TGH protein (B) and mRNA
(C) in homozygous TGH null mice. Es-x is a related
carboxylesterase migrating at higher Mr due to
additional glycosylation and is recognized by the
polyclonal anti-TGH peptide antibodies.
(D) Carboxylesterase activities in total liver homo-
genates. Bars in (D) represent means ± SD. *p <
0.05 versus WT.
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cause insulin resistance (Monetti et al., 2007).
To test the hypothesis that attenuation of TGH expression
leads to decreased VLDL secretion in vivo, we generated TGH
knockout mice. We examined the phenotype of these mice
with respect to VLDL secretion, hepatic lipid accumulation,
insulin regulation of glucose homeostasis, and the effect on
whole-body energy utilization.
RESULTS
Decreased Liver Lipase Activity in Tgh/ Mice
The strategy that we used to generate TGH null mice is shown in
Figure S1 (available online). Disruption of TGH in mice was
demonstrated by PCR of mouse genomic DNA (Figure 1A). To
verify the absence of the TGH protein, liver homogenates were
analyzed by immunoblotting with an antiserum that was raised
against the C-terminal 14 amino acid residues of mouse TGH
(Wang et al., 2007). TGH protein was undetectable in Tgh/
mice, and normal levels were maintained in Tgh+/ mice
(Figure 1B). The peptide used for immunization of rabbits shares
10 out of 14 residues with a related family member carboxyles-
terase 1 (Es-x), which is detected as the higher-migrating
immunoreactive band (Figure 1B). Figure 1C shows that specific
targeting was achieved since the expression of Es-x and another
carboxylesterase Es-22 was not affected. These two genes are
located in the same carboxylesterase gene cluster as TGH and
share 75% identity with TGH including 100% in the targeted
exon 5 (Dolinsky et al., 2004b). Ablation of Tgh expression
resulted in 30% reduction of the carboxylesterase activity in liver
homogenates (Figure 1D).
Decreased Plasma Lipid and ApoB in Tgh/ Mice
Next we tested the hypothesis that TGH is involved in the provi-
sion of substrates for VLDL secretion in vivo. Plasma phospho-
lipid (PL) concentration was not significantly altered in Tgh/
mice compared with WT controls (Table 1). TGH deficiency led
to decreased fasting plasma concentrations of unesterified
(free) cholesterol (FC), cholesteryl esters (CE), and TG by 17%,
25%, and 50%, respectively, and by 27%, 33%, and 25% in184 Cell Metabolism 11, 183–193, March 3, 2010 ª2010 Elsevier Inc.the fed state (Table 1). Decreased plasma
lipid levels were mainly due to reduction of
VLDL-sized particles (Figures 2A and 2B).
Correspondingly, plasma apoB100 levels
were markedly decreased in Tgh/
mice in both fasted (Figure 2C) and fed
(Figure 2D) states. Plasma apoB48 levelswere not significantly changed, possibly due to the ability of
this protein to be secreted on TG-poor particles.
To evaluate whether the decreased plasma apoB100 and TG
concentrations are a result of reduced secretion or increased
catabolism, we analyzed apoB and TG secretion in vivo.
[35S]Methionine was injected into the tail vein of mice, followed
by detergent P-407 administration to block lipolysis of secreted
lipoproteins by plasma lipases, therefore attenuating the uptake
of secreted lipoproteins through the LDL receptor pathway.
Secretion of newly synthesized labeled apoB and TG was in
a linear range for at least 3 hours following administration of
the radiolabeled amino acid (data not shown). The secretion of
newly synthesized apoB100 was significantly decreased in
Tgh/ mice (Figure 2E). Analysis of densities of newly secreted
apoB lipoproteins revealed that all apoB100 is present in lipid
enriched fractions, but the levels of apoB100 in all fractions
were lower in Tgh/ mice (Figure 2F), indicating compromised
apoB100 lipidation. Secretion of newly synthesized apoB48
was not affected in Tgh/ mice (Figure 2E), and apoB48-con-
taining particles were secreted from Tgh/ mice with a wider
density range compared to WT mice (Figure 2F). Despite
decreased lipidation and secretion of apoB100 from Tgh/
mice, TG secretion rates from WT and Tgh/ mice were similar
(214 ± 15.5 and 220 ± 65 mg/dl/hr, respectively) suggesting
compensatory TG association with apoB48-containing lipopro-
teins. MTP is responsible for the transfer of lipids to nascent
apoB and therefore is believed to represent the rate-limiting
step in VLDL assembly and secretion (Hussain et al., 2003; Kulin-
ski et al., 2002; Raabe et al., 1999; Tietge et al., 1999; Wang et al.,
1996). The level of MTP was not altered in Tgh/ mice, suggest-
ing that the observed decrease in VLDL secretion is independent
of MTP function (Figure S2).
Decreased VLDL Secretion from Isolated Hepatocytes
To further assess the mechanism of TGH-mediated mobilization
of stored cellular TG for VLDL assembly, primary mouse hepato-
cytes were isolated and lipid turnover studies were performed.
Hepatocytes were incubated in media containing [3H]oleic acid
(OA) and [14C]glycerol. Tgh/ hepatocytes exhibited 28.8%
and 41.1% decrease of [3H]OA-derived TG secretion during
Table 1. Phenotypic Comparison of Wild-Type and Tgh/ Mice
Fasted Fed
WT Tgh/ WT Tgh/
Plasma TG (mg/dl) 32.08 ± 21.17 22.79 ± 13.39* 38.69 ± 8.34 29.09 ± 2.87*
Plasma FC (mg/dl) 42.99 ± 8.80 37.73 ± 12.00* 41.20 ± 2.68 29.89 ± 4.32*
Plasma CE (mg/dl) 52.61 ± 12.22 42.80 ± 12.82** 46.48 ± 5.05 31.00 ± 7.20*
Plasma PL (mg/dl) 84.24 ± 29.66 89.20 ± 38.19 75.62 ± 9.77 63.94 ± 6.43
Liver TG (mg/mg protein) 257.94 ± 180.23 203.14 ± 108.30 23.52 ± 18.89 7.03 ± 4.27*
Liver FC (mg/mg protein) 16.99 ± 1.1 16.64 ± 1.17 15.20 ± 2.16 14.58 ± 2.32
Liver CE (mg/mg protein) 7.31 ± 3.89 4.49 ± 1.17 1.20 ± 0.51 0.92 ± 0.23
Liver PL (mg/mg protein) 76.46 ± 14.03 82.42 ± 11.79 60.48 ± 13.62 56.58 ± 21.89
Blood glucose (mmol/L) 2.57 ± 0.59 2.63 ± 0.45 6.60 ± 0.95 5.25 ± 0.59
Adiponectin (mg/ml) 7.20 ± 4.40 5.40 ± 1.79 8.80 ± 2.45 5.35 ± 1.73*
Leptin (ng/ml) 3.00 ± 2.44 3.33 ± 2.15 2.67 ± 1.57 2.91 ± 0.87
Insulin (pg/ml) 770.3 ± 387.1 396.3 ± 291.5 375.8 ± 222.4 419.2 ± 194.1
Resistin (pg/ml) 626.3 ± 330.4 441.3 ± 151.0 494.7 ± 206.2 691.0 ± 231.6
Male wild-type and Tgh/ mice (14- to 16-week old, n = 8–12 of each group) were fed a standard chow diet and were terminated in the fasted (fasting
for 16 hr) or fed (normal access to chow diet) state. Each value represents the mean ± SD. *p < 0.05, **p < 0.01 versus WT.
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Lipid and Glucose Metabolism in TGH-Null Micepulse or chase periods, respectively (Figure 3A). The secretion of
[14C]glycerol-derived TG from Tgh/ hepatocytes was also
significantly reduced (Figure 3B). Phosphatidylcholine (PC)
(Figures 3C and 3D) and CE (Figure 3E) secretion was not altered
by the ablation of Tgh expression.
The consequence of ablation of Tgh expression on cellular and
secreted lipid mass in isolated hepatocytes was evaluated
following incubation with 0.4 mM OA for 16 hr. OA supplementa-
tion increased TG mass in hepatocytes isolated from Tgh/
mice compared to hepatocytes isolated from WT mice in
agreement with the role of the enzyme in TG turnover
(Figure 3F). Additionally, intracellular CE levels increased from
2.08 ± 0.50 to 4.15 ± 0.55 mg/mg protein (p < 0.01) in TGH-defi-
cient hepatocytes upon OA supplementation. Cellular FC and PL
mass were not affected by the ablation of Tgh expression (data
not shown). In agreement with pulse-chase studies, primary
hepatocytes from TGH-deficient mice secreted less TG into
the media (Figure 3G), which could be mainly attributed to
decreased VLDL-TG secretion (Figure 3H). In the absence of
TGH, the secretion of apoB100 from isolated hepatocytes was
substantially reduced, while the secretion of apoB48 was
reduced only to a lesser degree (Figure 3I). Secreted albumin
levels were not affected by TGH deficiency, indicating that the
general secretory machinery in primary hepatocytes remained
unchanged.
Decreased VLDL Secretion from Human Hepatocytes
In order to examine whether decreased VLDL secretion due to
ablation of TGH activity in mice would be recapitulated in
humans, we have utilized primary human hepatocytes to study
the effect of attenuation of TGH activity on VLDL and apoB
secretion. Treatment of primary human hepatocytes with
a specific TGH inhibitor GR148672X (Gilham et al., 2003; Wei
et al., 2007b) reduced secretion of [3H]OA-labeled TG and
[14C]glycerol-labeled TG in both pulse and chase periods
(Figures 3J and 3K) but did not alter the secretion of labeled
PC (data not shown). In agreement with radiolabeling studies,CeTGH inhibitor reduced secretion of TG mass both in the presence
and absence of exogenously supplied OA by 40% and 50%,
respectively (Figure 3L). ApoB100 secretion was concomitantly
decreased by 25% (p < 0.05) (Figure 3M). Lipid mass analysis
showed that TGH inhibitor did not alter the cell TG level with
OA loading for 4 hr; however, the TG turnover was significant
decreased in the presence of TGH inhibitor (Figure 3N). These
results provide strong evidence for the role of TGH in VLDL
secretion in humans.
Absence of Fatty Liver in Tgh/ Mice
One possible side effect of decreasing hepatic lipolysis and
VLDL secretion is hepatic steatosis. The percentage of liver
weight with respect to body weight in TGH-deficient mice was
reduced by 11.4% (4.02 ± 0.19 [WT] versus 3.56 ± 0.19 [KO],
p < 0.05) and 19.6% (4.96 ± 0.32 [WT] versus 3.99 ± 0.31 [KO],
p < 0.01) in the fasted and fed states, respectively. Livers from
Tgh/ mice that were fasted for 16 hr had lipid storage compa-
rable to that of WT mice but exhibited significantly decreased TG
mass in mice that had normal access to chow diet (Table 1).
Similar results were obtained in females (data not shown). One
reason for lack of hepatic TG accumulation in Tgh/ mice
in vivo despite attenuated VLDL secretion could be through
decreased lipogenesis. Fatty acid synthase (FAS), stearoyl-
coenzyme A desaturase 1 (SCD-1), and acylCoA:diacylglycerol
acyltransferase (DGAT) catalyze committed steps in lipogenesis
(Chen and Farese, 2005; Millar et al., 2006; Owen and Zammit,
1997; Smith et al., 2000; Stone et al., 2004). TGH deficiency
did not affect TG synthesis from exogenously supplied fatty
acid in isolated primary hepatocytes (Figure S3A) or the hepatic
expression of Fas or Dgat, while Scd-1 expression was
decreased in fasted TGH KO mice (Figure S3B). Expression
levels of other genes encoding lipolytic enzymes including aryla-
cetamide deacetylase (AADA), adipose triglyceride lipase
(ATGL), and hormone-sensitive lipase (HSL) were not altered in
the livers of fasted TGH null mice (Figure S3B). The expression
of Aada and Atgl was increased in the fed state of Tgh/ micell Metabolism 11, 183–193, March 3, 2010 ª2010 Elsevier Inc. 185
Figure 2. Decreased Plasma Triacylglycerol, ApoB100 Levels, and Reduced In Vivo ApoB100 Secretion in TGH-Deficient Mice
(A–D) Plasma was collected from 12- to 14-week-old male mice, n = 6 for each genotype. Pooled plasma from fasted (A) and fed (B) mice was subjected to anal-
yses of TG content in lipoprotein fractions by fast-protein liquid chromatography. Two microliters of plasma from fasted (C) and fed (D) 12- to 14-week-old male
mice were electrophoresed in SDS 4%–15% gradient polyacrylamide gels; proteins were transferred to nitrocellulose membranes; and apoB, apoE, and albumin
levels were determined by immunoblotting.
(E) Decreased apoB100 secretion in vivo in Tgh/ mice. Male mice were fasted for 4 hr, after which 200 ml of PBS containing 250 mCi of [35S]methionine was
injected into a tail vein and P-407 (1 g/kg body weight) in saline was injected intraperitoneally. The animals were euthanized after 2 hr, apoB was immunopre-
cipitated from 100 ml of plasma and electrophoresed on SDS 5% polyacrylamide gels, and the gels were dried and exposed to X-ray films.
(F) Decreased lipidation of apoB in Tgh/ mice. Density of secreted newly synthesized apoB from pooled plasma from mice described above (E) was analyzed
by ultracentrifugation. Relative intensities of the immunoreactive or radioactive bands were determined by densitometry using Bio-Rad Quantity One
software. The ratio of specific apolipoprotein to albumin intensity in WT mice was assigned as 100%. Bars in (C)–(E) represent means ± SD. *p < 0.05,
**p < 0.01 versus WT.
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lower hepatic TG levels (Table 1).
The liver can also be protected from excessive TG accumula-
tion through diverting fatty acids into oxidation. Attenuation of
Tgh expression resulted in increased b-oxidation in primary
hepatocytes (Figure S3C), which was paralleled by augmented
mRNA levels of hepatic enzymes involved in the mitochondrial
b-oxidation of fatty acids, carnitine palmitoyltransferase I
(CPT-I), and long-chain acyl-CoA dehydrogenase (LCAD) in
fasted TGH null mice (Figures S3D and S3E). Messenger RNA
levels of acyl-CoA oxidase (ACO), an enzyme that participates
in the peroxisomal fatty acid oxidation, was not affected by the
disruption of the Tgh gene in either the fasted or the fed state
(Figure S3F). These results indicate that attenuation of Tgh
expression results in increased channeling of fatty acids into
oxidation.186 Cell Metabolism 11, 183–193, March 3, 2010 ª2010 Elsevier Inc.Decreased Plasma Fatty Acid Levels in Tgh/ Mice
TGH is also expressed in white adipose tissue (WAT), where it
may participate in TG turnover and fatty acid efflux (Dolinsky
et al., 2001; Soni et al., 2004; Wei et al., 2007b). Therefore,
another possible explanation for the absence of hepatic neutral
lipid accumulation in Tgh/ mice would be decreased delivery
of fatty acids from adipose tissue to the liver. Absence of TGH
protein in WAT of Tgh/ mice (Figure 4A) resulted in an approx-
imately 70% decrease of total in vitro hydrolase activity in WAT
homogenates (Figure 4B) and in a 70% increase of WAT weight
(Figure 4C). Augmentation in WAT weight in Tgh/ mice was
accompanied with increased WAT cell size (Figure 4D). Despite
the increased WAT, mass plasma fatty acid and glycerol concen-
trations in Tgh/ mice were 30% lower in both fed and fasted
conditions (Figures 4E–4H), indicating that lack of Tgh expres-
sion in WAT decreased TG mobilization in this tissue.
Figure 3. Decreased TGandApoBSecretion fromHepatocytes Isolated fromTGH-DeficientMice and fromHumanHepatocytes Treatedwith
TGH-Specific Inhibitor
Secretion of TG, but not PC and CE, was reduced from primary hepatocytes from WT and Tgh/ mice (A–E) and human hepatocytes treated with a TGH-specific
inhibitor (J and K). TG accumulation in TGH-deficient mouse hepatocytes incubated with 0.4 mM OA (F) and in human hepatocytes (decreased TG turnover)
treated with TGH-specific inhibitor (N). Decreased TG mass (G), VLDL-TG (H), and apoB100 (I) secretion from TGH-deficient hepatocytes and from TGH-inhib-
itor-treated primary human hepatocytes (L and M). Bars in (A)–(G) and (J)–(N) represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 versus WT.
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levels were lower in both fasted and fed state in Tgh/ mice
(Table 1), while plasma levels of leptin and resistin were similar
between the WT and Tgh/ mice (Table 1). No differences
were observed in plasma levels of inflammatory markers
TNF-a and IL-6 (data not shown).CeIncreased Metabolic Rate in Tgh/ Mice
Tgh/ mice fed chow did not exhibit increased body weight
(Figure 5A) despite significant increase in food intake compared
to WT mice (Figure 5B). This is likely due to increased energy
expenditure in Tgh/ mice, as measured by oxygen consump-
tion (Figure 5C). The augmented respiratory quotient (RQ)ll Metabolism 11, 183–193, March 3, 2010 ª2010 Elsevier Inc. 187
Figure 4. TGH-Deficient Mice Have
Reduced Hydrolase Activity in WAT and
Decreased Plasma Free Fatty Acid and
Glycerol Levels
(A) Immunoblot of TGH and loading control (PDI)
in WAT.
(B) Hydrolase activity in WAT homogenates.
(C) Epidydimal WAT mass.
(D–H) (D) Histological analysis of WAT. Plasma
glycerol levels in fed (E) and fasted (G) mice.
Plasma FFA levels in fed (F) and fasted (H) mice.
Ten-week-old female mice (n = 6) were analyzed.
Bars in (B), (C), and (E)–(H) represent means ±
SD. *p < 0.05, **p < 0.01, ***p < 0.001 versus WT.
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and protein for energy production over lipid oxidation. These
data are consistent with decreased fatty acid release from
WAT in TGH-deficient mice. TGH-deficient mice also exhibited
increased locomotor activity (Figure 5E), which may contribute
to the increased energy consumption.
Improved Glucose Tolerance and Insulin Sensitivity
No significant changes in glucose or insulin levels were observed
in TGH null mice when compared with control animals (Table 1).
In oral glucose tolerance tests (Figure 6A), Tgh/ mice dis-
played a markedly improved glucose tolerance compared with
WT mice. In insulin tolerance tests (Figure 6B), the maximal
decline of blood glucose levels was more pronounced in Tgh/
mice (5.48 mmol/L) than in WT mice (3.44 mmol/L) and persisted
during the entire measurement period. Improved insulin sensi-188 Cell Metabolism 11, 183–193, March 3, 2010 ª2010 Elsevier Inc.tivity in Tgh/ mice resulted in de-
creased hepatic expression of gluconeo-
genic genes glucose-6-phosphatase
(G6P) and phosphoenolpyruvate carbox-
ykinase (PEPCK) during the fed state
(Figure S4A) and in increased levels of
the glycolytic enzyme glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)
(Figure S4B).
Improved Pancreatic Islet Function
in Tgh/ Mice
Insulin secretion is sensitive to plasma
and b cell lipid levels (Corkey et al.,
1989; Mulder et al., 2004; Muoio and
Newgard, 2006; Prentki et al., 1992;
Yaney and Corkey, 2003). Mouse pancre-
atic b cells express low levels of TGH
(Figures S4C and S4D), and ablation of
Tgh expression did not affect islet intra-
cellular lipase activity (Figure S4E) or
TG levels (Figure S4F), possibly due to
compensatory increased expression of
Hsl (Figure S4G) and Atgl (Figure S4H),
since the expression of TG synthetic
genes Dgat1 and Dgat2 was not changed
(Figures S4I and S4J). Islets isolated from
Tgh/ mice displayed normal glucose
stimulated insulin secretion (Figure S4K). Immunohistochemistry
of representative pancreatic sections showed a remarkable
decrease in total islet area in Tgh/ mice compared to WT
mice (Figure 6C).
DISCUSSION
TG is required for proper assembly of secretion-competent
apoB-containing lipoproteins (Adiels et al., 2008; Fisher and
Ginsberg, 2002; Gibbons et al., 2000). In the absence of suffi-
cient amounts of TG for VLDL assembly, apoB is targeted to
degradation (Fisher and Ginsberg, 2002; Fisher et al., 1997).
The goal of this study was to test the hypothesis that an ER-local-
ized TGH plays an important role in VLDL assembly and energy
metabolism in vivo. We found that ablation of Tgh expression
resulted in the reduction of total liver carboxylester hydrolase
Figure 5. TGH-Deficient Mice Have
Increased Energy Expenditure
Adult (20-week-old) male mice were used to
analyze body weight (A); food intake (B); energy
consumption, with inset showing mean ± SD
over a 24 hr period (C); RQ (D); and locomotor
activity, with inset showing mean ± SD over a
24 hr period (E). n = 6 for each group. Bars in
(A)–(E) represent means ± SD. *p < 0.05, **p < 0.01,
***p < 0.001 versus WT.
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both fasted and fed state. Parallel decreases were found in
plasma apoB100 levels. Lipidation of the secreted apoB100
was markedly diminished. Secretion of apoB48 was not
affected, probably because unlike apoB100, apoB48 can enter
the secretory pathway in a relatively poorly lipidated form.
Surprisingly, we did not observe any differences in TG secretion
rate between WT and Tgh/ mice, although the ablation of
Tgh expression decreased in vivo apoB100 secretion and
reduced TG and apoB100 secretion from primary hepatocytes.
Similar outcomes were observed using either Poloxamer-407
or Triton WR1339 methodologies. One possibility is that these
methods might not have been sensitive enough to pick up
changes in TG secretion that accompanied decreased secretion
of apoB100. Unaltered rate of apoB48 secretion in vivo from
Tgh/ mice suggests that TG secretion associated with
apoB48 could obscure the reduction of TG secretion associated
with apoB100 in Tgh/ mice. Our results support a role of TGH
for the assembly of apoB100-lipoproteins. Unlike attenuation of
VLDL secretion by the inhibition of MTP, which leads to fatty liver
(Chandler et al., 2003; Cuchel et al., 2007; Raabe et al., 1999),
ablation of Tgh expression does not provoke excessive hepatic
TG deposition even during fasting. Although accretion of hepatic
TG was not observed in vivo, the ablation of Tgh expressionCell Metabolism 11, 183–1facilitated about 3-fold accumulation of
TG in isolated hepatocytes incubated
with exogenous fatty acid, indicating
that TGH-mediated energy metabolism
in other tissues is an important regulator
of hepatic lipid levels.
Indeed, our previous studies have
shown that attenuation of TGH activity in
3T3-L1 cells decreased fatty acid release
without affecting glucose uptake (Wei
et al., 2007b). In the fed state (when
plasma insulin levels are high), adipose
tissue HSL and ATGL are not active, but
basal lipolysis continues (Haemmerle
et al., 2006; Schweiger et al., 2006),
possibly through the activity of TGH
(Soni et al., 2004; Wei et al., 2007b).
Therefore, absence of accumulation of
hepatic TG levels in TGH-deficient mice
might be a consequence of decreased
TGH-mediated TG mobilization in WAT.
Ablation of Tgh expression in WAT
resulted in decreased hydrolase activityaccompanied with reduced plasma fatty acid and glycerol levels.
A reciprocal relationship exists between the use of fatty acids
and glucose as substrates for energy production (Galgani
et al., 2008). In agreement with decreased fatty acid release
from WAT, TGH null mice exhibited increased RQ, which indi-
cates overall preferential metabolism of carbohydrates over
fatty acids. TGH null mice consumed significantly more
energy compared to WT mice without body weight gain, which
suggested altered energy metabolism. Indeed, Tgh/ mice
exhibited improved glucose tolerance and insulin sensitivity
and increased locomotor activity. It is well known that high levels
of circulating fatty acids result in abnormally high deposition of
lipids in various organs (Bergman and Ader, 2000; Galgani
et al., 2008). Excessive lipid infiltration of organs is believed to
be one of the main causes of impaired insulin sensitivity in the
liver, skeletal muscle, and pancreas (Bergman and Ader, 2000;
Leclercq et al., 2007). It is probable that the observed reduction
of fatty acid release from WAT in Tgh/ mice is one of the
reasons for the observed lack of TG accumulation in the liver
and pancreatic b cells, leading to augmented insulin sensitivity.
As a result, the expression of key enzymes related to hepatic
gluconeogenesis, G6P and PEPCK, was reduced, suggesting
that TGH deficiency leads to decreased hepatic glucose output
and improved hepatic insulin sensitivity. It has been shown that93, March 3, 2010 ª2010 Elsevier Inc. 189
Figure 6. TGH-Deficient Mice Are More
Glucose and Insulin Tolerant
(A and B) (A) Oral glucose and (B) insulin tolerance
tests were performed in 10-week-old male mice
(n = 6) fasted for 4 hr. Bars in (A) and (B) represent
means ± SD. *p < 0.05, ***p < 0.001.
(C) Immunohistochemistry of pancreata.
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glucose-stimulated insulin secretion, at least in part by inhibition
of glucose oxidation and proinsulin transcription and translation
(Cnop, 2008). In this study, we observed an ameliorated b cell
function by TGH deficiency. The size of pancreatic islets is
determined by the metabolic state. Under conditions of
increased metabolic load, increased basal serum insulin levels,
or obesity-associated insulin resistance, the islet size tends to
become larger (Harada et al., 2003; Rhodes, 2005; Roduit
et al., 2001; Shen et al., 2007). In agreement with the observed
improved insulin and glucose tolerance in TGH-deficient mice,
the islets in these mice were significantly smaller compared to
WT mice.
Improved insulin sensitivity in TGH-deficient mice may be
a consequence of ablation of Tgh expression in all tissues (liver,
adipose tissue, and islets). The importance of TGH expression
in individual tissues to the overall energy homeostasis will be
answered by tissue-specific TGH knockout mice that are
currently under development in our laboratory.
In conclusion, our results support a role of TGH not only in
VLDL assembly but in the whole-body energy metabolism.
Importantly, by using cultured primary human hepatocytes
we show for the first time that our findings in mouse models190 Cell Metabolism 11, 183–193, March 3, 2010 ª2010 Elsevier Inc.recapitulate the behavior of the human
TGH enzyme. Because TGH deficiency
showed only positive effects on the
overall energy homeostasis (decreased
secretion of atherogenic lipoproteins
without fatty liver, increased glucose tol-
erance, lower apparent metabolic insult
to pancreatic b cells), TGH represents
an ideal pharmacological target.
EXPERIMENTAL PROCEDURES
Generation of Tgh/ Mice
A gene-targeting vector was designed to replace
exon 5 that encodes the catalytic Ser221 residue
(Dolinsky et al., 2001) with a neo cassette
(Figure S1). An 10.5 kb region used to construct
the targeting vector was first cloned from a
positively identified BAC clone. The region was
designed such that the short homology arm (SA)
extended 1.8 kb 30 to exon 5. The long homology
arm (LA) ended at the 50 side of exon 5 and is
7.8 kb long. The Neo cassette replaced 850 bp
of the gene, including exon 5. The targeting vector
was confirmed by restriction analysis after each
modification step and sequencing. Ten micro-
grams of the targeting vector were linearized by
AscI and then transfected by electroporation
of iTL 129SVev embryonic stem cells. After selec-tion in G418, surviving clones were expanded for PCR analysis to identify
recombinant ES clones. Primer A2 (50-ACCAGCTGCCAGAGATTTCAG-30)
was designed downstream (30) to the SA outside the region used to generate
the targeting construct. PCR reactions using A2 with the N1 primer (50-TGCG
AGGCCAGAGGCCACTTGTGTAGC-30) at the 50 end of the Neo cassette
amplifies a 2.3 kb fragment. Tgh/ mice were also genotyped by a three-
primer PCR reaction designed to distinguish homozygosity from heterozy-
gosity, where the targeted allele gave a 2.4 kb fragment (primers N1 and A3
[50-AGTTCATCCTCTGTCTTCTGG-30 ]) and the wild-type allele gave a 2.9 kb
fragment (primers 144F [50-TCAGCCTTGACTCTTCTAACC-30] and A3).
All animal procedures were approved by the University of Alberta’s Animal
Case and Use Committee and were in accordance with guidelines of the Cana-
dian Council on Animal Care. Mice, housed three to five per cage, were
exposed to a 12 hr light/dark cycle beginning with light at 8:00 a.m. Adult
male and female mice were fed ad libitum a chow diet from LabDiet (PICO
laboratory Rodent Diet 20) and had a free access to water. Adult male (12- to
24-week-old) mice, all background (129P2) and age matched, were used in
the experiments unless specified otherwise.
Blood and Plasma Parameters
Blood samples were collected from tail veins. Plasma levels of TG, FC, CEs,
and phospholipids were determined by gas chromatography. Blood glucose
was monitored using blood glucose strips and the Accu-Check glucometer
(Roche Diagnostics, Vienna, Austria). Plasma concentrations of insulin, leptin,
resistin, TNF-a, and IL-6 were measured using Mouse Serum Adipokine Linco-
plex kit. Plasma adiponectin concentrations were determined using mouse
Cell Metabolism
Lipid and Glucose Metabolism in TGH-Null Miceadiponectin radioimmunoassay. All adipokine and cytokine measurements
were performed by Millipore Corporation, Billerica, MA. Plasma fatty acid
levels were determined using NEFA C commercial kit according to the
manufacturer’s protocol (Wako Chemicals GmbH, USA). Plasma glycerol
levels were determined using the Serum Triglyceride Determination Kit
(Sigma, USA).
RNA Isolation and PCR Analysis
Total RNA was isolated using Trizol reagent (Life Technologies, Inc.). First-
strand cDNA synthesis from 2 mg of total RNA was performed using Super-
Script II reverse transcriptase (Invitrogen) primed by oligo(dT)12–18 primers.
The transcripts of TGH, Es-x, and Es-22 were evaluated by PCR analysis.
Real-time qPCR was employed to detect other transcripts related to fatty
acid oxidation, lipogenesis, gluconeogenesis, glycolysis, and lipolysis.
Detailed procedures for real-time qPCR are presented in the Supplemental
Information. All primers were synthesized at the DNA Core Facility of the
University of Alberta. Primers for the various genes are listed in Table S1.
Carboxylester Hydrolase Activity Assay
Tissues were homogenized in 50 mM Tris-HCl (pH 7.4), 250 mM sucrose, and
1 mM EDTA, using a glass/Teflon homogenizer followed by sonication for 20 s.
A fluorescence-based assay using 4-methyl umbelliferyl heptanoate (MUH) as
a substrate was performed essentially as described previously (Alam et al.,
2006; Gilham et al., 2005; Gilham and Lehner, 2005).
Determination of Tissue Lipids
The mass of tissue TG, phospholipids, cholesterol, and CEs was determined
by gas chromatography as described previously (Sahoo et al., 2004; Wei
et al., 2007a).
Hepatic TG and ApoB Production In Vivo
Mice were fasted for 4 hr and injected with 100 ml of PBS containing 250 mCi of
[35S]methionine via tail vein, and P-407 (1000 mg/kg body weight) in saline was
injected intraperitoneally. One hundred microliters of blood was taken before
and 1 hr after injection. Two hours following the injection of P-407, time that
was shown to be in the linear range for hepatic TG and apoB production (Millar
et al., 2005), blood samples were collected and plasma was isolated and pro-
cessed for analyses as described as follows. To 100 ml of plasma were added
800 ml of PBS, 100 ml 103 immunoprecipitation buffer (1.5 M NaCl, 0.5 M
Tris$Cl [pH 7.4], 50 mM EDTA, 5% [v/v] Triton X-100 and 1% [w/v] SDS) and
10 ml goat anti-human apoB IgG. The mixture was incubated on a rotating
rack overnight at 4C, after which 50 ml of protein A Sepharose was added
and the mixture was further incubated for 3 hr. The beads were pelleted by
brief centrifugation and were washed three times with excess immunoprecip-
itation buffer, followed by denaturing electrophoresis sample buffer. Samples
were boiled and underwent electrophoresis in SDS 5% polyacrylamide gels.
Gels were stained by Coomassie blue, dried, and exposed to X-ray films. Equal
aliquots of plasma samples were also immunoprecipitated with goat anti-
human apoB antibodies and separated by electrophoresis; apoB48 and
apoB100 proteins were visualized by Coomassie blue, excised, and dissolved
at 60C in 0.2 ml of 60% perchloric acid followed by 0.4 ml of 30% hydrogen
peroxide (Gilham et al., 2003; Lehner and Vance, 1999). Radioactivity associ-
ated with apoB48 and apoB100 was determined by using the Hionic-Fluor
scintillation cocktail (Packard Instrument, Meriden, CT) and scintillation count-
ing. The total radioactivity in plasma before immunoprecipitation was also
determined.
Plasma at 2 hr after injection of P-407 was subjected to ultracentrifugation to
isolate apoB-containing lipoprotein of various densities (Kulinski et al., 2002).
Brieftly, 200 ml of pooled plasma samples collected from WT and Tgh/ mice
were combined with 1.3 ml of PBS, mixed with 0.7 g of KBr, and placed in
a 5.0 ml Quick-Seal tube. The sample was overlaid with 3.5 ml of 0.9%
NaCl. The samples were centrifuged at 416,0003 g for 1 hr in a VTi 65.2 rotor.
Ten fractions, 0.5 ml each, with densities ranging from 1.006 g/ml (fraction 10)
to 1.21 g/ml (fraction 1), were collected from the bottom of the tube. ApoB was
precipitated by Cab-O-Sil from each fraction and analyzed by electrophoresis
on SDS 5% polyacrylamide gels. The gel was stained, dried, and exposed to
X-ray film.CeIsolation of Primary Hepatocytes
Primary mouse hepatocytes were isolated by collagenase perfusion of the
livers from male wild-type (WT) and Tgh/ mice that had been fed ad libitum.
Hepatocytes were plated on collagen-coated 60 mm dishes (Corning, Nepean,
Ontario, Canada) at 2.0 3 106 cells/dish and incubated for 5 hr in DMEM
containing 15% FBS at 37C in humidified air containing 5% CO2 to allow cells
to attach.
Human hepatocytes were prepared by dissociation of liver fragments
obtained from hepatectomies performed for therapeutic purposes at the
Service of Digestive Tract Surgery, University of Alberta. The operations
were performed for intrahepatic hemangioma, colorectal metastasis, or
benign liver tumor; segments of human liver tissue (15–20 cm3) were obtained
from resection specimens far away from the tumor margin. All patients gave
their consent to participate. The study was approved by the University of
Alberta Ethics Committee. Cell counts (hemocytometer) and viability (trypan
blue exclusion) were confirmed before use; viability was routinely >80%.
Hepatic Lipid Turnover and Secretion
Primary mouse hepatocytes were incubated for 4 hr in 2 ml of DMEM contain-
ing 5 mCi [3H]OA complexed with 0.4 mM OA/ 0.5% fatty acid-free BSA and
0.5 mCi [14C]glycerol. After the 4 hr incubation, some cells and media were
collected for analysis (pulse). Remaining dishes were washed with PBS and
incubated for 1 hr with DMEM to allow secretion of lipoproteins containing
newly synthesized lipids. Cells were then incubated with DMEM for 4 hr and
cells and media were collected for analysis of secretion of preformed lipids
(chase). Lipids were extracted, resolved by thin-layer chromatography, and
analyzed as described in the Supplemental Information. To evaluate the lipid
mass secreted by primary hepatocytes, cells were incubated with 2 ml
DMEM containing 0.4 mM OA/ 0.5% fatty acid-free BSA for 16 hr. After
incubation, cells and media were collected for lipid analysis by gas chromatog-
raphy and lipoprotein profile analysis by FPLC (Sahoo et al., 2004; Wei
et al., 2007a).
Incubations of primary human hepatocytes were performed as described
above for mouse hepatocytes except that 10 mM TGH-specific inhibitor
GR148672X was included as specified.
Secretion of ApoB from Primary Hepatocytes
Primary mouse hepatocytes were incubated for 4 hr with DMEM containing
0.4 mM OA complexed to 0.5% BSA in order to increase intracellular TG
stores. Cells were then washed and incubated for 16 hr with 2 ml of DMEM.
Media were removed and briefly centrifuged to remove cellular debris. Lipid
mass in cells and media was determined using gas chromatography. Apolipo-
proteins and albumin were collected from media by Cab-O-Sil and analyzed by
immunoblotting (Gilham et al., 2003).
Metabolic Measurements
Measurements of oxygen consumption (VO2) and RQ with indirect calorimetry
were performed on mice at 20 weeks of age. Animals were maintained on a
standard chow diet under 12 hr light and dark cycles beginning at 6:00 a.m.
and 6:00 p.m., respectively. Mice were acclimated in individual chambers for
2 days before recording. Measurements of VO2 were recorded every 14 min
over 2 days using the Oxymax System (Columbus Instruments, Columbus,
OH). RQ equals volumes of CO2 released/volumes of O2 consumed.
Oral Glucose Tolerance and Insulin Tolerance
Prior to oral glucose tolerance, mice were fasted for 3 hr. Then a dextrose solu-
tion (3 mg/g body weight) was administered by oral gavage. Glucose levels
were monitored before and at 15, 30, 60, and 120 min postgavage using blood
glucose strips (Roche Diagnostics, Vienna, Austria).
For insulin sensitivity determinations, mice were fasted for 4 hr and injected
intraperitoneally with 1 U bovine insulin/kg of body weight. Blood was
collected before injection and 15, 30, 60, 120 min after injection, and glucose
levels were determined as described above.
Immunohistochemical Analysis of Pancreata
Pancreas was removed using standard blunt dissection techniques and placed
in Z-fix for 24 hr, embedded in paraffin, and sectioned at 3 mm thickness onto
Histobond slides. The resulting slides were stained for insulin-positive cellsll Metabolism 11, 183–193, March 3, 2010 ª2010 Elsevier Inc. 191
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Lipid and Glucose Metabolism in TGH-Null Miceusing standard ABC-DAB immunohistochemistry techniques and observed
under a standard light microscope as previously described (Korbutt et al.,
1996).
Statistical Analysis
Data are presented as means ± SD employing unpaired two-tailed t test. Oral
glucose tolerance test, insulin sensitivity test, VO2, and RQ were analyzed by
two-way ANOVA followed by Bonferroni post test (GraphPad PRISM 4 soft-
ware). Five to six animals were used in each experimental group. P < 0.05
was interpreted as a significant difference.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, four figures, and one table and can be found with
this article online at doi:10.1016/j.cmet.2010.02.005.
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